Heat Biologics Inc (NASDAQ:HTBX) recently release the results of its Non-Muscle invasive Bladder Cancer treatment Phase-II study. The company is developing this ImPACT-based treatment for the patients suffering from NMIBC. The HS-410 Bladder Cancer Treatment was designed on the same lines of principles as its HS-110 treatment. The company explains that the treatment on which it is presently working is based on the knowledge about antigens that the bladder cancer patients share and suffer from.
Phase II trial of HS-410 Bladder Cancer Treatment: The Progress Report
In its latest press release about the treatment, Heat Biologics said that “there were encouraging signs of anti-tumor activity” among 94-patients enrolled in the study to evaluate HS-410 (vesigenurtacel-L). The study focussed largely on combination of its treatment with Bacillus Calmette-Guérin (BCG). Also, how well did it perform as a monotherapy, was also a matter of study.
The latest results revealed that the treatment is capable of generating antigen-specific immune response for a range of peptides that are related to tumor. The response of such a kind was absent in case of placebo.
The company believes that this strong signal response of the vaccine proves it to be impactful and responsive in managing challenges of the disease.
Finding an alternative to BCG as the only treatment for NMIBC
If we look at the past figures related to Non-Muscle invasive Bladder Cancer, we learn that the disease has been a difficult one to deal with. There was just a singular treatment that could fight against it, and it was BSG. Actually, from past 40 years, BSG has remained the solely approved treatment for the same.
With Heat Biologics finding a way out to this singularity, there is a scope for the patients to explore more options. Also, it will leave the company in a stronger threshold, from where it can move further.
It is interesting to see here that the USFDA gave its fast approval to this vaccine/treatment, given the need of its existence as an alternative.